Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.

NCT04108468 is registered in ClinicalTrials.gov with The Leeds Teaching Hospitals NHS Trust as lead sponsor.

NCT NCT04108468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04108468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.
Lead sponsor
The Leeds Teaching Hospitals NHS Trust
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2015
Completion date
July 31, 2023
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis